TURALIO acts as a CSF-1 regulator to target the tumor and interrupt cell signaling responsible for tumor growth and inflammation1,2
Pexidartinib is a small-molecule tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF-1R), KIT proto-oncogene receptor
tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation
Overexpression of the CSF-1R ligand promotes cell proliferation and accumulation in the synovium


TURALIO is the first FDA-approved targeted therapy for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery1,3
DOSAGE